在ESR1-突变乳腺癌中,ESR1 F404突变和获得的富尔维斯坦抗性
Belinda Kingston1, Alex Pearson1, Maria Teresa Herrera-Abreu1
1The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
Cancer discovery
|November 20, 2023
概括
新的ESR1突变 (F404) 在晚期乳腺癌中可能导致对富勒韦斯特兰的耐药性. 这些突变,特别是结合起来,突出显示了对口服ER降解剂的潜在耐药性,指导了未来的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 富尔韦斯坦是激素受体阳性晚期乳腺癌的关键治疗方法.
- 获得的富勒韦斯特兰抗药性,特别是由于ESR1突变,限制了治疗的有效性.
- 了解耐药机制对于开发有效疗法至关重要.
研究的目的:
- 在具有激活ESR1突变的患者中调查获得的富勒韦斯特兰抗药性.
- 为了确定新的ESR1突变,并描述它们对富尔韦斯兰特结合和敏感性的影响.
- 评估口服ERα降解剂对抗耐药突变模型的疗效.
主要方法:
- 来自PlasmaMATCH队列A患者的循环瘤DNA (ctDNA) 的分析.
- 基线和治疗结束 (EOT) ctDNA样本的测序.
- 在ESR1突变的in silico建模及其与fulvestrant的相互作用.
- 在具有特定ESR1突变的细胞模型中对药物敏感性的体外分析.
主要成果:
- 4%的患者在cis中获得了具有激活突变的新型ESR1 F404突变 (F404L,F404I,F404V).
- 在模型中显示F404突变破坏了富尔韦斯特兰特与ERα的结合.
- 化合物突变 (例如,D538G + F404L) 赋予了对富尔韦斯特兰特的耐药性.
- 几种口服ERα降解剂对化合物突变模型表现出活性.
结论:
- 新的ESR1 F404突变代表了晚期乳腺癌中富尔韦斯特兰特耐药性的机制.
- 结合ESR1突变可能导致药物特异性耐药性,影响口服ER降解剂的有效性.
- 这些发现确定了对富尔韦斯特兰特耐药患者的新治疗点.
更多相关视频
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K